Oppenheimer analyst Suraj Kalia raised the firm’s price target on Abbott (ABT) to $140 from $134 and keeps an Outperform rating on the shares following quarterly results. The firm’s constructive outlook assumes subsiding non-MedTech headwinds, easier comparable sales in FY26, and top-line composite growth ticking up to low double digits, along with EBIT margins.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott Laboratories: Strong Performance and Resilience Justify Buy Rating Amid Economic Challenges
- Abbott price target raised to $142 from $132 at Raymond James
- Abbott price target raised to $145 from $140 at BTIG
- Abbott price target raised to $145 from $133 at Piper Sandler
- Abbott Laboratories: Strong Performance and Strategic Positioning Drive Buy Rating